SynOx appoints Philip Astley-Sparke as chairman

SynOx Therapeutics Ltd has appointed a seasoned biotech executive as chairman to support the company’s evolution into a global, commercially focused biotechnology company. SynOx’s treatment called emactuzumab for tenosynovial giant cell tumours (TGCT) is in a Phase 3 registrational trial and the company is focusing on global regulatory filings, commercial readiness and increasing its transatlantic footprint. Mr Astley-Sparke has over two decades of experience in building and leading innovative companies across immuno-oncology and rare diseases. He has guided multiple organisations from early-stage through to BLA filing with the US Food and Drug Administration and commercial launch preparations. He is currently executive chairman at Replimune Group. Mr Astley-Sparke succeeds Ton Logtenberg, who has been chair of the board since 2021.

SynOx announced the appointment on 1 April 2025.